Who are BISMUTH TETRACYCLINE METRONIDAZOLE OMEPRAZOLE's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/bismuth-tetracycline-metronidazole-omeprazole.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

BISMUTH TETRACYCLINE METRONIDAZOLE OMEPRAZOLE — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

BISMUTH TETRACYCLINE METRONIDAZOLE OMEPRAZOLE (BISMUTH TETRACYCLINE METRONIDAZOLE OMEPRAZOLE) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: H. pylori eradication therapy (quadruple therapy). Area: Gastroenterology / Infectious Disease.

marketed H. pylori eradication therapy (quadruple therapy) Helicobacter pylori (bacterial pathogen); omeprazole targets H+/K+-ATPase Gastroenterology / Infectious Disease Small molecule Live · refreshed every 30 min

Target snapshot

BISMUTH TETRACYCLINE METRONIDAZOLE OMEPRAZOLE (BISMUTH TETRACYCLINE METRONIDAZOLE OMEPRAZOLE) — The University of Texas Health Science Center, Houston. This is a quadruple therapy combining bismuth subsalicylate, tetracycline, metronidazole, and omeprazole to eradicate Helicobacter pylori through multiple antimicrobial and acid-suppression mechanisms.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
BISMUTH TETRACYCLINE METRONIDAZOLE OMEPRAZOLE TARGET	BISMUTH TETRACYCLINE METRONIDAZOLE OMEPRAZOLE	The University of Texas Health Science Center, Houston	marketed	H. pylori eradication therapy (quadruple therapy)	Helicobacter pylori (bacterial pathogen); omeprazole targets H+/K+-ATPase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (H. pylori eradication therapy (quadruple therapy) class)

The University of Texas Health Science Center, Houston · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). BISMUTH TETRACYCLINE METRONIDAZOLE OMEPRAZOLE — Competitive Intelligence Brief. https://druglandscape.com/ci/bismuth-tetracycline-metronidazole-omeprazole. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab